Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Duke University Hospital

  • Home
  •  
  • Duke University Hospital



  • Most Read
  • Latest Comments
  • Cyclopharm makes US entry with Duke University Hospital the first contract for Technegas
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Cyclopharm makes US entry with Duke University Hospital the first contract for Technegas
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Cyclopharm makes US entry with Duke University Hospital the first contract for Technegas
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Cyclopharm makes US entry with Duke University Hospital the first contract for Technegas
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Cyclopharm makes US entry with Duke University Hospital the first contract for Technegas
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Cyclopharm makes US entry with Duke University Hospital the first contract for Technegas
    Cyclopharm makes US entry with Duke University Hospital the first contract for Technegas
    • News

  • Cyclopharm gets FDA green light to sell its lung imaging tech Technegas in the US
    Cyclopharm gets FDA green light to sell its lung imaging tech Technegas in the US
    • News

  • The blip in Cyclopharm’s plans for FDA approval
    The blip in Cyclopharm’s plans for FDA approval
    • News

  • Cyclopharm submits FDA application, expects 50% market share within 3 years
    Cyclopharm submits FDA application, expects 50% market share within 3 years
    • News

  • Cyclopharm makes US entry with Duke University Hospital the first contract for Technegas
    • News

    Cyclopharm makes US entry with Duke University Hospital the first contract for Technegas

    After gaining US FDA approval in September 2023, nuclear medicine company Cyclopharm (ASX: CYC) has made an official entry into the country with the signing of its inaugural commercial contract for Technegas in the United States with Duke University Hospital the first institution to enter into a formal agreement to use Technegas. Technegas, an imaging

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.